Hypogonadism Drug Market By Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), Therapy Type (Testosterone Replacement Therapy and Steroid Replacement Therapy), Mechanism of Action Type (Steroidal Androgens &Gonadotropins), Route of Administration (Oral, Injectable, Tropical), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026
Market Analysis: Global Hypogonadism Drug Market
Global hypogonadism drug market is rising gradually with a substantial CAGR in the forecast period of 2021-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.
Download Full Sample Report Of Hypogonadism Drug Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market
Market Definition: Global Hypogonadism Drug Market
Hypogonadism is a rare endocrine disorders characterized by insufficient production of testosterone hormone due to failure of testicles. This hormone is essential for functioning of sexual characteristics. The person with hypogonadism may experience weakness, loss of libido, infertility and osteoporosis.
According to the article published in Clarus Therapeutics, it was estimated that over 7.00 million testosterone replacement related drug prescriptions were prescribed by physician. Growing population of hypogonadism and robust pipeline for development of newer therapies are the key factors for market growth.
Market Drivers
Increase in prevalence rate of hypogonadism worldwide acts as a driver for the market
Increase in the rate of research and development initiatives is driving the market
Rising awareness about hypogonadism therapy and technological advancement is driving the market growth
Ongoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market
Market Restraints
Effective treatment is either unavailable or unaffordable
Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the market
Inadequate knowledge about hypogonadism in some developing countries
Segmentation: Global Hypogonadism Drug Market
By Type
- Hypergonadotropic Hypogonadism
- Hypogonadotropic Hypogonadism
By Therapy Type
- Testosterone Replacement Therapy
- Steroid Replacement Therapy
By Treatment
- Medication
- Hormone therapy
- Surgery
By Mechanism of Action Type
- Steroidal androgens
- Testosterone
- Methyltestosterone
- Gonadotropins
- Chorionic Gonadotropin
- Follicle Stimulating Hormone
By Route of administration
- Oral
- Injectable
- Topical
By End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Geography
- North America
- S.
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Rest of South America
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Turkey
- Belgium
- Netherlands
- Switzerland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- South Korea
- India
- Australia
- Singapore
- Thailand
- Malaysia
- Indonesia
- Philippines
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Egypt
- Saudi Arabia
- United Arab Emirates
- Israel
- Rest of Middle East & Africa
Key Developments in the Market:
In March 2019, Clarus Therapeutics received the FDA approval for Jatenzo (testosterone undecanoate), an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. This approval represents the first oral treatment option for hypogonadism in men.
In October 2018, Antares Pharma received the FDA approval for Xyosted (testosterone enanthate) Injection, a testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. The FDA approval of Xyosted expanded the company’s branded portfolio in therapeutic area of endocrinology.
Competitive Analysis:
Global hypogonadism drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global hypogonadism market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the global hypogonadism drug market are AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne and many others.
Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market
Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hypogonadism-drug-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
Browse Related Reports @
PDLC (Polymer Dispersed Liquid Crystal) for Smart Window Market